e-learning
resources
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Panel discussion: Improving the pathway of lung cancer patients, can we do it better?
A. Šajnic (Zagreb, Croatia), T. Blum (Berlin, Germany), Prof. Marko Jakopovic (Zagreb, Croatia), A. Breški (Zagreb, Croatia), I. Belina (Zagreb, Croatia), G. Hardavella (Athens, Greece), M. J. Catarata (Porto, Portugal)
Source:
ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better?
Number:
0
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Šajnic (Zagreb, Croatia), T. Blum (Berlin, Germany), Prof. Marko Jakopovic (Zagreb, Croatia), A. Breški (Zagreb, Croatia), I. Belina (Zagreb, Croatia), G. Hardavella (Athens, Greece), M. J. Catarata (Porto, Portugal). Panel discussion: Improving the pathway of lung cancer patients, can we do it better?. ERS webinar 2021: Panel discussion on improving the pathway of lung cancer patients, can we do it better?
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration
Source: Eur Respir J 2009; 34: 1477-1486
Year: 2009
Reducing delays in lung cancer diagnostic pathways to improve patient experience
Source: International Congress 2016 – Quality management and quality of life in lung cancer
Year: 2016
Novel survey tool used to assess priorities of lung cancer patients and carers
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
The two week wait pathway: Is it used appropriately?
Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours
Year: 2014
Lung cancer survival in the UK: are the results from the national lung cancer audit (LUCADA) dependent on completeness of case reporting?
Source: Annual Congress 2009 - Epidemiology and management of lung cancer
Year: 2009
Oncogenic drivers (OD) and matched targeted agents (TA): Impact on overall survival in patients with lung adenocarcinoma (LA)?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Lung cancer screening: the critical review
Source: International Congress 2015 – Lung cancer screening: how to implement a comprehensive preventive approach
Year: 2015
Lung function in the elderly patients with a diagnosis of lung cancer - A challenge for the surgical treatment?
Source: International Congress 2015 – Surgery and lung cancer: results and complications
Year: 2015
Muldisciplinary conference (MDC), oncological program (OP) and practice guidelines (GL): The experience of the lung cancer (LC) clinic of a cancer hospital
Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours
Year: 2014
Improving NLST criteria for lung cancer screening
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
Is time from "referral to diagnosis" in lung cancer pathway affected by diagnostic test delays?
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Active TB in cancer patients: A missed screening opportunity?
Source: International Congress 2015 – Screening strategies in TB
Year: 2015
Does bronchial location of lung cancer influence overall survival?
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
Do doctors understand the test characteristics of lung cancer screening? – A randomized trial
Source: International Congress 2016 – A view into a chest and pleural pathology
Year: 2016
Screening for lung cancer: who should (not) be enrolled?
Source: International Congress 2019 – NELSON: the Trafalgar of lung cancer screening?
Year: 2019
A network lung cancer pathway in review: Are we choosing the right diagnostic approach?
Source: Annual Congress 2010 - Quality management for lung cancer patients
Year: 2010
National lung cancer tissue diagnosis targets: Are they achievable?
Source: International Congress 2014 – Improving diagnosis of thoracic tumours
Year: 2014
COPD and lung cancer: Prevalence, infradiagnosis, phenotypes and multidimensional characterization
Source: International Congress 2016 – Epidemiology and specific subgroups in lung cancer
Year: 2016
Population’s understanding and degree of participation of a screening lung cancer programme
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept